Stevanato Group S P A Stock Price, News & Analysis

Stevanato Group (NYSE: STVN) announced its participation in the Bank of America Global Healthcare Conference on September 15, 2022, at 9:05 a.m. BST in London. The event highlights the company's role as a leading provider of drug containment and delivery solutions. Interested investors can access a webcast via the company's website under the 'News & Events' section. Founded in 1949, Stevanato Group provides integrated solutions for the pharmaceutical and life sciences industries, focusing on innovation and engineering excellence.

Stevanato Group (NYSE: STVN) and Gerresheimer AG have announced their collaboration to develop a new Ready-To-Use (RTU) vial solution based on Stevanato's EZ-fill® technology. This initiative aims to enhance quality, efficiency, and reduce the total cost of ownership for pharmaceutical companies. The partnership addresses the rising demand for RTU vials, with a focus on standardizing fill-finish operations. The new solution will significantly lower particle load, bolstering overall quality. The platform will be showcased at the CPhI Worldwide in Frankfurt in November 2022.

Stevanato Group (NYSE: STVN) reported a strong second quarter of 2022, achieving a 15% revenue growth to €234.2 million. The company raised its full-year guidance, projecting revenue between €955 million and €965 million. Adjusted diluted EPS was €0.12, with a 31.8% gross profit margin. The backlog rose 37% to approximately €1.01 billion, driven by increased demand in Biopharmaceutical and Diagnostic Solutions. Despite lower COVID-19-related revenue, the Core business showed robust demand.

Stevanato Group (NYSE: STVN) will release its second quarter 2022 financial results on August 4, 2022, at 6:30 a.m. EST. A conference call and webcast will follow at 8:30 a.m. EST to discuss the results, accompanied by a slide presentation available on their Investor Relations webpage. Interested participants can pre-register for immediate access. The company provides drug containment, delivery, and diagnostic solutions for the pharmaceutical and biotechnology sectors, emphasizing its engineering and innovation capabilities.

Stevanato Group S.p.A. (NYSE: STVN) announced that all resolutions proposed at its Annual General Meeting (AGM) on June 1, 2022 were approved. This includes the approval of annual financial statements for the year ending December 31, 2021 and the distribution of dividends of EUR 0.051 per share, with a record date of June 14, 2022 and a payment date of July 13, 2022. Shareholders also granted new authorization for share buybacks and amendments to the articles of association.

Stevanato Group (NYSE: STVN) announced its participation in two upcoming investor conferences. On June 7, 2022, they will present at the 42nd Annual William Blair Growth Stock Conference in Chicago at 2:40 PM CST. The following day, on June 9, 2022, they will be at the Jefferies Healthcare Conference in New York City at 1:00 PM EST. Live audio webcasts will be available on their website, with replays accessible for 90 days.

Stevanato Group (NYSE: STVN) has announced the acquisition of a 65,000-square-meter industrial complex in Cisterna di Latina, Italy. This facility aims to enhance the company’s production capabilities in response to rising demand for its drug containment solutions. The new site will employ approximately 190 people and partially utilize renewable energy sources. Operations are set to commence in 2023, boosting the production of standard and EZ-fill® solutions. CEO Franco Moro emphasizes the strategic expansion in a major pharmaceutical hub to better serve customer needs.

Stevanato Group (NYSE: STVN) reported a 10% revenue increase in Q1 2022, totaling €212.1 million. Diluted EPS stood at €0.10, with adjusted diluted EPS at €0.11. The backlog surged 49% to €992.2 million, driven by a 29% rise in high-value solutions. Gross profit margin improved to 31.8%, although production faced temporary slowdowns due to Covid-related absenteeism. The company maintains its fiscal 2022 guidance, projecting revenue between €935 million and €945 million and adjusted diluted EPS between €0.49 and €0.51.